| |
Monday, April 21, 2025 | 12pm ET / 9am PT Join us for an exclusive webinar exploring groundbreaking findings from the DUTRENEO trial, which evaluated the role of predictive biomarkers in guiding neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). Register today. 
|
|
Today’s Big NewsApr 8, 2025 |
|
Access this resource for key insights from industry leaders on the use of in-country liquid biopsy testing for global clinical trials. Country-specific regulations often prevent or delay access to testing results, decreasing population sizes and increasing timing and costs. Download now to see how to overcome these challenges. 
|
|
| By Gabrielle Masson As President Donald Trump’s massive overhaul of federal agencies continues, several former FDA officials spoke about the potential ramifications for drug reviews and provided a look inside current FDA conditions. |
|
|
|
By Angus Liu Although President Trump’s “Liberation Day” tariffs have spared pharmaceuticals, potential drug-specific import levies remain a sword of Damocles creating anxiety among biopharma companies. Some industry leaders now fear that more than $100 billion in investments could leave the European Union. |
By James Waldron A U.S. congressional commission has made the case for “swift action” to maintain the nation’s role as a biotech superpower while warning the sector is “dangerously close to falling behind China.” |
By Zoey Becker The HHS secretary called out the measles vaccines as "the most effective way" to prevent the spread as an outbreak in Texas claims a second life. |
|
Scaling advanced biotherapeutics is becoming more complex due to the rise of therapies like cell and gene treatments, RNA therapeutics and monoclonal antibody variants. Access this report to discover key strategies to optimize production, ensure compliance and accelerate commercialization. Download now. 
|
|
By Darren Incorvaia The Trump administration has blocked access to multiple data repositories maintained by the National Institutes of Health (NIH) for researchers in several countries, including a cancer statistics database used regularly by scientists in China. |
By Conor Hale Prapela’s device provides gentle, randomized movements that aim to trigger and regulate the brain’s control of breathing, without being strong enough to wake up the baby from sleep. |
By Andrea Park As the countdown to the launch of its first therapeutic continues, Rocket Pharmaceuticals is fueling up its commercial team. |
By Fraiser Kansteiner Looking to grow production in Latin America’s biggest country, Novo Nordisk is charting a $1.09 billion expansion at its manufacturing plant in Brazil. The investment will “significantly” bolster the facility’s capacity to crank out a variety of injectables, including GLP-1 medicines like Ozempic and Wegovy, Novo said in an announcement. |
By Zoey Becker Nordic Capital confirmed that it doesn't intend to make an offer for PureTech Health shortly after buyout discussions were disclosed by PureTech. |
By Conor Hale The revamped Kandu will move forward with $30 million in new financing, through a round co-led by Ally Bridge Group and AMED Ventures. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we dive into our special report ranking the top pharma R&D budgets for 2024. |
|
|---|
|
|
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
Whitepaper Avoid costly mistakes and ensure your clinical development program meets the highest standards by reading WCG’s whitepaper on Imaging Core Labs, Endpoint Adjudication Committees (EAC), and other safety reviews. Sponsored by: WCG |
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| Accepting Nominations Now |
|
| Accepting Nominations Now |
|
|
| |
|
+(1)+(1).png)
